venoplant gdue biotrap argivit duonorm aurastop venoplant gdue biotrap argivit duonorm aurastop venoplant gdue biotrap argivit duonorm aurastop

Ursolisin

Ursodeoxycholic acid

Ursolisin

Active substance

Ursodeoxycholic acid

Strenght and pharmaceutical forms

​150 mg hard capsules – 20 hard capsules
150 mg hard capsules – 30 hard capsules
150 mg hard capsules – 40 hard capsules
300 mg hard capsules – 10 hard capsules
300 mg hard capsules – 20 hard capsules

ATC

A05AA02 - Hepatobiliary antilithogen, litolithic

Therapeutic Indications

Qualitative and quantitative alterations of biligenetic function, including bile-overexpressing cholesterol forms, to oppose the formation of cholesterol calculations or to achieve conditions for dissolution if radiolucent calculations already exist: in particular, gallbladder stones in functional gallbladder and calculations in residual choledocus or recurrent ones after surgery on the bile ducts; Biliary dyspepsia.

Marketing Authorization Holder

Magis Farmaceutici S.r.l.

Download area

Summary of Product Characteristics - Ursolisin

Clinical Review from British Journal of Medicine & Medical Research


Products of the same therapeutic areas

Events

05/07/24

La chirurgia gastroenterologica high-tech: dall'integrazione tecnologica all'intelligenza artificiale

Maglie

"La chirurgia gastroenterologica high-tech: dall'integrazione tecnologica all'intelligenza artificiale"

 Download

28/06/2024

“SCENARI FUTURI IN EPATOLOGIA 2024”

SPOLETO (PG)

 

 Download